Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.30 | N/A | +11.92% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.30 | N/A | +11.92% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in their product pipeline and market position. However, they did not provide specific guidance for future quarters.
Management highlighted strong performance in key therapeutic areas.
They noted ongoing investments in R&D to drive future growth.
Amgen's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. The stock's slight increase of 0.64% reflects investor confidence, driven by strong performance in key areas. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BARRICK MNG CORP
Oct 24, 2014